MPAL stands for mixed phenotype acute leukemia, a rare acute leukemia with blasts expressing markers of multiple lineages. It is considered a high-risk leukemia subtype with complex biology.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06991920 |
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage |
NOT_YET_RECRUITING | NA |
